Michelle Thomas

Director, Europe
Healthcare

Michelle joined CG Results as a consultant in December 2020 and is now a Director within the Healthcare Team. Michelle brings over 25 years of experience from various Financial roles within the Healthcare sector including the last 13 in Corporate Finance, and has extensive experience in structuring, negotiating and valuing all types of transactions from Public and Private M&A, asset acquisitions, product in and out-licencing, product divestments, co-development/promotion agreements and Venture Fund Investments.

Michelle was key member of the Core Deal Team at Shire plc for 10 years. As part of this Team, she was involved in the negotiation and due diligence of all Corporate Development transactions assessed by the Company and responsible for the financial evaluation of a transaction. Headline deals included the acquisitions of Baxalta for $32B, Dyax for $6.2B, NPS for $5.2B and ViroPharma for $4.1B.

In her spare time, Michelle enjoys endurance cycling, hiking, skiing and sailing.

To learn you have to listen, to improve you have to try - Thomas Jefferson

Latest Insights

Reports
23rd November 2022

Pharma Licensing – an introduction

We are pleased to share our introduction to Pharma Licensing. This guide provides an overview of both in and out-licensing as well as insights on what to anticipate during the process. We hope that you find this guide useful and look forward to discussing the underlying themes with you. Do get in touch! Click to […]

Insights
17th October 2022

Pharma Licensing: the why the how and a few things to get right

Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP).  IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios.  A pharma licensing deal […]